UPB
Upstream Bio, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$455.50M
P/E Ratio
—
EPS
$-2.90
Beta
—
52W High
$33.68
52W Low
$7.25
50-Day MA
$9.27
200-Day MA
$18.52
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.32M |
| Gross Profit (TTM) | $3.32M |
| EBITDA | $-171.77M |
| Operating Margin | -4218.00% |
| Return on Equity | -41.80% |
| Return on Assets | -27.80% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $6.26 |
| Price-to-Book | 1.50 |
| Price-to-Sales (TTM) | 137.11 |
| EV/Revenue | 48.53 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 82.70% |
| Shares Outstanding | $54.42M |
| Float | $35.01M |
| % Insiders | 14.88% |
| % Institutions | 90.05% |
Historical Volatility
HV 10-Day
68.43%
HV 20-Day
51.95%
HV 30-Day
51.93%
HV 60-Day
70.22%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($42.43 target)
2
Strong Buy5
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026